| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Vegetative Physiology, University of Cologne, Koeln, Germany
2 Department of Cardiovascular Medicine, University of Oxford, UK
3 Department of Pediatrics, Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital, Cincinnati, OH 45229-3039, USA
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
(Received 11 November 2004;
accepted after revision 11 February 2005;
first published online 17 February 2005)
Corresponding author M. Kruger: Dept. of General Zoology and Genetics, Westfälische Wilhelms University of Muenster, Schlossplatz 5, D-48149 Muenster, Germany. Email: makruger{at}uni-muenster.de
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
To date, more than 15 missense mutations on the cTnI molecule have been identified in patients suffering from FHC (Kimura et al. 1997; Seidman & Seidman, 2001). To identify the underlying pathological mechanism of disease development, a number of investigators have studied the effects of FHC-related mutations on actomyosin ATPase and on contractile steady-state properties of skinned fibres and cardiomyocytes (Elliott et al. 2000; Takahashi-Yanaga et al. 2001; Burton et al. 2002; Lang et al. 2002; Westfall et al. 2002; Kohler et al. 2003). The most intensively studied cTnI mutation is located within the inhibitory region at position 145, replacing a positively charged arginine by an uncharged glycine (Kimura et al. 1997). Controversial data for Ca2+ sensitivity of force development aside, in vitro studies consistently show that the mutation R145G leads to an increase in ATPase activity at resting [Ca2+] (Elliott et al. 2000; Takahashi-Yanaga et al. 2001; Lang et al. 2002).
Most of the pathological manifestations of this mutation observed in the human heart could be reproduced in a transgenic mouse model expressing the corresponding mutation R146G in the murine cTnI (mcTnI) (James et al. 2000). Interestingly, the phenotype of the transgenic mice depends on the amount of expressed mcTnIR146G. If the mutated protein makes up more than 50% of the total mcTnI protein the mice develop cardiomyocyte disarray, interstitial fibrosis and suffer premature death. In contrast, if the mutated protein contributes to the total mcTnI by only 40%, no pathological alterations in cellular and organ morphology were reported. Surprisingly, working heart analyses of these animals revealed impaired isovolumetric relaxation, indicated by a more than 2-fold prolonged lifetime of pressure fall (
), a relatively load-independent measure of diastolic function (James et al. 2000). Coexistent to impaired relaxation, systolic function was improved as indicated by significantly increased values of +dP/dt. These data and similar data on transgenic mice overexpressing FHC-related mutations in other sarcomeric proteins (Evans et al. 2000) reflect the clinical observation in FHC patients, which typically exhibit normal and sometimes even supra-normal contractile function, while lusitropy is severely impaired (Kass et al. 2004).
Studies performed on intact trabeculae revealed that the rate-limiting steps of cardiac contraction and relaxation reside in the myofilaments (Janssen et al. 2002). This makes crossbridge kinetics and altered kinetics of regulatory proteins possible candidates for the altered haemodynamics observed in FHC. To date the effects of FHC mutations in myosin heavy chain, TnT and Tm on crossbridge kinetics have been investigated in skinned fibres where kinetics are derived from force transients induced by mechanical stretch or release (Palmiter et al. 2000). To our knowledge, no study has investigated the effect of FHC-related mutations on force kinetics in a myofibrillar system, in which isometric contraction and relaxation are induced by the physiological activator [Ca2+]. Thus the question of whether the impaired diastolic function observed in FHC might be related to impaired force kinetics during myofibrillar relaxation remains to be answered.
In this study we investigated the effects of the FHC mutation R145G in cTnI on the force kinetics of isolated myofibrillar bundles, in which contraction and relaxation is induced by changes in [Ca2+] via rapid solution change (Stehle et al. 2002b). We used two different strategies to introduce the mutation into the myofibrils. In one approach, we applied a recently developed biochemical technique to exchange the native Tn in myofibrils with exogenous, recombinant troponin complexes (Kruger et al. 2003). In the second method we investigated force kinetics in cardiac myofibrils isolated from mcTnIR146G transgenic mice. By comparing the data we obtained a detailed analysis of the impact of cTnIR145G on the kinetics of force activation and relaxation. Furthermore, we suggest possible adaptational processes in myofibrillar function that could be manifested during the development of heart failure in the transgenic animals.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The three human cardiac troponin subunits hcTnCwt, hcTnTwt and hcTnI (either hcTnIwt or hcTnIR145G) were expressed separately in E. coli and purified as previously described (Kruger et al. 2003). The identity of the plasmids was verified by sequencing. The purified subunits were reconstituted to the heterotrimeric hcTn complex (Potter, 1982) that was then stored at 4°C for up to 1 week.
Isolation of cardiac myofibrils
For the experiments on myofibrils from mcTnIR146G transgenic, adult FVB/N mice in which 40% of the endogenous cTnI was replaced with mcTnIR146G were used (James et al. 2000). For the hcTn exchange experiments myofibrils were prepared from adult Him: OF 1 mice. Mice were killed by cervical dislocation. All experiments were approved by the Institutional Animal Care and Use Committee.
The heart was removed and papillary muscles were dissected from the left ventricle, skinned with 1% v/v Triton-X 100 in rigor buffer (132 mmol l–1 NaCl, 5 mmol l–1 KCl, 1 mmol l–1 MgCl2, 10 mmol l–1 Tris pH 7.1, 5 mmol l–1 EGTA, 1 mmol l–1 NaN3 and a protease inhibitor cocktail) for 2 h and stored at 4°C in rigor buffer without Triton-X 100. Myofibrillar suspensions were prepared immediately before experiments by homogenizing skinned papillary muscles with a blender (Ultra Turrax) for 10 s at 4°C.
Exchange of hcTn complex in mouse cardiac myofibrils
Replacement of native mcTn by recombinant hcTn was performed with a protocol adapted and modified for cardiac myofibrils (Kruger et al. 2003), which was initially described for skeletal muscle fibres by Brenner et al. (1999) and also for skinned cardiac fibres (Kohler et al. 2003). In brief, reconstituted hcTn complex was dialysed against rigor buffer, centrifuged at 13 000 g for 10 min and filtered through a polypropylene mesh (Millex-HV, 0.45 µm pore, Durapore) to remove aggregates. The freshly prepared myofibril suspension was centrifuged for 5 min at 380 g (10°C), the myofibril pellet resuspended in rigor buffer containing hcTn complex (1 mg ml–1) and incubated at 21°C for 60 min. To remove excess Tn, myofibrils were washed by centrifugation in rigor buffer (5 min at 380 g, 10°C). Exchange of the troponin subunits was confirmed by Western blot analysis as reported previously (Kruger et al. 2003). The protein components were separated on SDS-PAGE, transferred onto a nitrocellulose membrane (Schleicher & Schuell GmbH, Dassel, Germany) by standard tank transfer Western blot and probed by a monoclonal antibody against cTnI (clone 6F9, Dunn Labortechnik GmbH, Asbach, Germany) which also recognizes sTnI and a monoclonal anti-TnT antibody (JLT12, Sigma-Aldrich, Taufkirchen, Germany). The membranes were incubated with anti-mouse IgG-HRP (Sigma-Aldrich, Taufkirchen, Germany) and enzymatic activity was detected using an ECL-kit (Amersham Biosciences, Freiburg, Germany).
Myofibrillar force measurements
Myofibrillar force kinetics were measured as previously described (Stehle et al. 2002a,b; Kruger et al. 2003). Composition of relaxing (pCa 7.5) and activating solution (pCa 4.5) was as in Stehle et al. (2002b). Using silicone adhesive, small myofibrillar bundles 5–10 µm in diameter and 40–70 µm in length were attached in relaxing solution to a stiff micro-needle at one end and to the tip of an atomic force cantilever at the other end. After mounting, the bundles were stretched to a sarcomere length of 2.3 µm. To avoid possible errors caused by phase contrast, determination of sarcomere length and cross-sectional area (CSA) were performed in bright field. Rapid changes (
10 ms) in Ca2+ concentration were applied to the myofibrils using the solution change technique described in Stehle et al. (2002b). Force transients were recorded by monitoring the deflection of the cantilever by laser light reflection (Stehle et al. 2002a). All experiments were performed at 10°C.
Data analysis and statistics
To determine force kinetic parameters, original force transients were fitted by either a mono-exponential function to derive kACT or by a function consisting of a linear and an exponential term to derive kLIN, tLIN and kREL (Stehle et al. 2002b). Statistical analysis was performed by subjecting the data to Student's t test. Significance was determined as *P < 0.05, **P < 0.01 and ***P < 0.001. Unless otherwise noted, all data are given as mean ± S.E.M. (standard error of the mean) of n experiments.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
|
Force–sarcomere length relationships were measured by stretching myofibrils (pCa 7.5) from slack sarcomere length of 2.0 µm to defined sarcomere length (SL) ranging from 2.2 to 2.6 µm. In this SL range, regular sarcomere patterns were observed in all myofibrils. In both experimental models, myofibrils containing mutant cTnI showed an increased upward shift of the force–SL relationship compared with either non-transgenic (ntg) (Fig. 2A) or hcTnWT (Fig. 2B). It is noteworthy that the slopes of the force–SL relationships were not altered by the mutant protein as would be expected if passive length-dependent stiffness properties were changed.
|
Ca2+ dependence of force development and Ca2+-induced force development kinetics
Maximum Ca2+-activated force at pCa 4.5 normalized to cross-sectional area (Fmax/CSA) is significantly decreased by 24% in mouse myofibrils exchanged with hcTnIR145G compared with hcTnIWT-exchanged controls (see Table 1). In contrast, no difference in Fmax/CSA was observed for myofibrils isolated from transgenic mice when compared with those isolated from non-transgenic controls. The values for Fmax/CSA are given in Table 1.
|
|
30% in the hcTnIR145G myofibrils and by 15% in myofibrils isolated from mcTnIR146G transgenic mice. The values for kACT after Ca2+ activation with pCa 4.5 are given in Table 1.
|
|
Rapidly deactivating myofibrils by changing the [Ca2+] from pCa 4.5 to 7.5 induced a biphasic relaxation (see Fig. 4 for typical force transients): an initial linear force decay followed by a fast exponential decay. The slow linear phase has a rate constant kLIN and a duration tLIN (Stehle et al. 2002b) while the exponential phase is described by the rate constant kREL. Figure 6 shows the values obtained for the parameters kLIN and tLIN of the initial force decay. Neither myofibrils exchanged with hcTnIR145G nor myofibrils isolated from mcTnIR146G transgenic mice differed in their values of kLIN compared with their hcTnIWT or non-transgenic controls, respectively (Fig. 6A). In myofibrils isolated from the transgenic mice the duration of the linear phase tLIN was unaltered compared with the corresponding non-transgenic mice (Fig. 6B), whereas myofibrils exchanged with hcTnIR145G showed a 1.7-fold longer tLIN (P < 0.005) than those exchanged with hcTnIWT.
|
40% of the values for hcTnIWT-exchanged myofibrils. In myofibrils from the transgenic mice kREL is reduced by 27% compared with controls. In both models kREL was also significantly reduced in relaxations initiated from partial activations with pCa 5.75 and 5.51 (Fig. 7). The values for kLIN, tLIN and kREL in relaxation experiments following maximum Ca2+ activation are summarized in Table 1.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We find it unlikely that the differences are due to the hybrid system for the following reasons: in recent studies we compared steady-state and kinetic contractile parameters in native murine myofibrils with those exchanged with hcTn and with native human myofibrils (Stehle et al. 2002b; Kruger et al. 2003). The kinetic parameters were an order of magnitude higher in the native as well as in the exchanged murine myofibrils compared with the native human myofibrils indicating that the kinetic parameters are not sensitive to the Tn isoform. Fmax/CSA was lower in the exchanged myofibrils as also seen in this study. At present we do not know whether this is due to the exchange procedure per se or is a reflection of the hybrid system. Irrespective of the cause of the depression in force, it is larger in myofibrils exchanged with hcTnIR145G indicating that this mutation has a specific effect on Fmax/CSA. Therefore we propose that in the transgenic myofibrils the gene dosage may be too low to affect Fmax/CSA.
The impact of transgenic expression of R145G on myosin isoform content has been explored at both the RNA levels, via 
- and ß-myosin heavy chain-specific oligonucleotide probes (Ng et al. 1991) and by titrating the two proteins directly using a general and ß-myosin-specific antibody (Krenz et al. 2003). Transcript levels were up slightly (less than 10%) but no detectable changes in the relative or absolute levels of the myosin isoforms were detected. We therefore conclude that altered expression of MHC isoforms does not contribute to the observed differences between the transgenic mice and the myofibrils from normal mice exchanged with the troponin mutant. It remains to be seen whether there are adaptational changes in the expression of other sarcomeric proteins, which may account for the differences. Taken together our results indicate that biochemically exchanged murine cardiac myofibrils are a suitable model to study the direct effects of hcTnI mutations on the activation–relaxation cycle.
Increased force–sarcomere length relationship at low [Ca2+]
Regardless of the model system used – transgenic or biochemical exchange – the cTnI mutation R145G caused a significant upward shift of the force–SL relationship at pCa 7.5 when compared with myofibrils containing the wild-type isoform. It is known from previous studies that isoform switching of titin, one major element determining myofibrillar stiffness, can alter passive myofibrillar force properties during cardiomyopathy (Neagoe et al. 2002). However, since myofibrils exchanged with hcTnIR145G in vitro also exhibit increased force in the absence of Ca2+ we can exclude that any compensatory alterations in elastic elements such as titin contribute to this effect. Instead, it strengthens our hypothesis that the increased force–SL relationship observed here is caused by incomplete inhibition of force-generating crossbridges by the troponin complex. This is further supported by the finding that addition of 5 mM BDM, an inhibitor of myosin ATPase (Zhao et al. 1995), can partially reverse the upward shift of the force–SL relationship. Our data are in agreement with previous findings reporting increased ATPase activity and increased isometric force under relaxing conditions (pCa 9) in myofilaments and exchanged skinned fibre preparations carrying the same cTnI mutation (Takahashi-Yanaga et al. 2001; Burton et al. 2002; Lang et al. 2002).
Ca2+ sensitivity of force activation
In myofibrils from mcTnIR146G transgenic mice we observed a slight, but significant decrease in Ca2+ sensitivity of force development, manifested by a reduction of pCa50 values. Myofibrils exchanged with hcTnIR145G in vitro did not show any significant effects on Ca2+ sensitivity of force development. While this is somewhat puzzling, there are conflicting data in the literature for the influence of cTnIR145G on the Ca2+ sensitivity of force development. Incorporation of cTnIR145G in skinned fibre preparations from guinea-pig heart had no effect on Ca2+ sensitivity (Burton et al. 2002), while in skinned fibre preparations from porcine left ventricle the R145G mutation induced a significant increase in Ca2+-sensitivity and ATPase-activity (Takahashi-Yanaga et al. 2001; Lang et al. 2002). Similarly, in skinned fibre preparations from mcTnIR146G transgenic mice the Ca2+ sensitivity of force development is increased (James et al. 2000). The question of what causes the different effects of the FHC mutation R145G on Ca2+ sensitivity in the different preparations still remains to be answered. Species-specific differences aside, many factors could possibly influence the effect of the mutation on the Ca2+ sensitivity, such as pH or the mutant-to-wild-type ratio (Elliott et al. 2000). Much more pronounced than the change in pCa50 observed in this study was the strong loss of cooperativity indicated by the gradient of the force–pCa relationship (Fig. 2). Thus, at very low activating [Ca2+], we actually observed an increase in Ca2+-activated force instead of a decrease, which correlates with the differences observed in the pCa–kACT relationship discussed below. These results parallel findings previously described for skinned fibre preparations exchanged with the R145G mutation, showing relative isometric force to be increased at low [Ca2+], whereas force development at high [Ca2+] is significantly decreased (Burton et al. 2002; Lang et al. 2002).
We note that the cooperativity of Ca2+ activation in the analysed non-transgenic myofibrils (Hill coefficient >10) is much higher than those which had been found in skinned trabeculae from this mouse model (James et al. 2000). High Hill coefficients had been also reported for single skinned cardiomyocytes (Brandt et al. 1998). One reason for this could be that variability in Ca2+ sensitivity among individual myocytes generating the force in a multicellular preparation would add together to yield a less steep force–pCa relationship than those of the individual myocyte. The subcellular myofibrils investigated here might be therefore a more sensitive model than skinned trabeculae to detect changes in cooperativity.
Kinetics of Ca2+-induced force activation
By investigating values for kACT after activation with different [Ca2+] we showed that regardless of the experimental method used, the mutation cTnIR145G affects kACT at both low and high [Ca2+] (Fig. 5). At low [Ca2+]
kACT is increased, whereas at high [Ca2+] it is decreased. There is experimental evidence that kACT is rate-limited by crossbridge turnover kinetics (Stehle et al. 2002a; Tesi et al. 2002; Palmer & Kentish, 1998; Moss et al. 2004 and references cited within). Application of a fast slack–restretch sequence to an activated (pCa 4.5) myofibril results in tension redevelopment with kinetic values kTR, which are similar to kACT. This implies that the Ca2+-induced switch-on of the regulatory system is a very rapid process occurring before the onset of tension development and therefore cannot directly rate-limit the rate constant of force development kACT. This is further corroborated by our previous report that human cardiac myofibrils exhibit 10-fold lower values of kACT than cardiac myofibrils isolated from mice (Stehle et al. 2002a). If kACT was rate-limited by the switch-on kinetics of the Tn complex, one would expect exchange of human cTn into murine myofibrils to slow down myofibrillar force kinetics. However, here we report that incorporation of human wild-type troponin complex into murine cardiac myofibrils has no impact on the values of kACT when compared with values found in native myofibrils isolated from non-transgenic mice (Table 1). It therefore seems unlikely that the troponin isoforms directly contribute to the observed effects of the mutation on the activation kinetics. Instead, we favour a model in which force development kinetics are primarily rate-limited by turnover kinetics of the crossbridge cycle (Stehle et al. 2002a; Martin et al. 2004). The cTn–Tm complex rapidly fluctuates between off (Ca2+ bound) and on (no Ca2+ bound) states (Brenner & Chalovich, 1999). It thereby regulates the probability and thus the apparent rate constant for the formation of force-generating crossbridges. The effects of the cTnI mutation on the Ca2+ dependences of force and kACT could therefore be explained by an increased fraction of cTn–Tm units in on-states at low [Ca2+], leading to increased values of kACT, and a reduced fraction at high [Ca2+], leading to the significantly decreased values of kACT after activation with pCa 4.5. This implies that the mutation impairs two different functions of the TnI molecule: first, to fully inhibit force-generating actomyosin interactions at low [Ca2+], and second, to release this inhibition at high [Ca2+]. This leads to the hypothesis that the amino acid at position R145 is required for the proper interaction of TnI with TnC in the Ca2+-bound state. This is supported by studies on the inhibitory peptide, which has been shown to be sufficient to partially restore Ca2+ regulation of actomyosin ATPase (Tripet et al. 1997) and force (Van Eyk et al. 1993). In particular, Li et al. (2003) demonstrated that the R145G mutation decreases the affinity of the isolated inhibitory peptide for TnC.
Kinetics of force relaxation
During relaxation, kLIN, the rate constant of the initial slow linear phase, was not significantly affected by the cTnI mutation in both the in vitro exchange preparations and the transgenic myofibrils. Although kLIN is difficult to determine accurately in murine cardiac myofibrils because of their extremely rapid turnover kinetics, we can exclude that the mutation changes this parameter by more than 20%. Previous studies revealed that during the initial slow linear phase of relaxation all sarcomeres remain isometric (Stehle et al. 2002a) and several lines of evidence in other species suggest that no significant recruitment of new force-generating crossbridges occurs during this phase (for review see Poggesi et al. 2005). We therefore assume that also in the mouse the rate constant kLIN is predominantly determined by the apparent rate by which crossbridges leave force-generating states under isometric conditions (Stehle et al. 2002a; Tesi et al. 2002). The fact that kLIN is not altered suggests that the cTnI mutation has no effect on the decay of force-generating crossbridges during this relaxation phase.
The initial linear relaxation phase ends at a time tLIN after Ca2+ removal. As reported previously (Stehle et al. 2002a), this is the time point when the first, mechanically weakest, sarcomere in a myofibril elongates, thereby initiating the fast exponential relaxation phase. During sarcomere relaxation in this phase crossbridge detachment rates increase in all sarcomeres, regardless of their lengthening or shortening, and crossbridges leave force-generating states by increased rates of backward turnover kinetics in currently relaxing sarcomeres. This releases the strain on the other sarcomeres and allows the remaining crossbridges to leave force-generating states by rapid forward kinetics (Stehle et al. 2002a). Different to the rate constant kLIN during the linear relaxation phase, kREL is therefore determined by the rapid crossbridge detachment in the presence of sarcomere dynamics (Stehle et al. 2002a).
We showed that incorporation of hcTnIR145G into isolated myofibrils leads to a prolongation of tLIN by 70% compared with hcTnIWT-exchanged myofibrils. This implies that the sarcomeres remain isometric for a longer time during relaxation. It is not quite clear at present by which mechanism the mutation delays the initiation of the fast relaxation phase. One factor may be the mechanical strain on the individual crossbridges (cf. Poggesi et al. 2005 for review). Reduced force leads to reduced strain inhomogeneities within the elastic elements of the sarcomeres and thereby reduces the probability of relaxation onset in the weakest sarcomere. Hence, the increase in tLIN may be related to the decreased Ca2+-activated force (Fmax/CSA) in the myofibrils exchanged with hcTnIR145G. Consistent with this interpretation, tLIN was not altered in myofibrils isolated from the transgenic cTnIR145G mice, in which Fmax/CSA remained unchanged, compared with non-transgenic control mice. However, as this interpretation is consistent only within each of the two models but not between them, additional, but as yet unknown, factors must come into play.
The most prominent effect of the mutation common to both models was the decelerated fast exponential phase of force relaxation. In both models, the mutation decreased the rate constant kREL of this phase to 60–70% of the wild-type or non-transgenic control, respectively. Tesi et al. (2002) showed in skeletal myofibrils that kREL depends very sensitively on the final steady-state force after relaxation. They found kREL to be decreased 3- to 4-fold whereas kLIN remains unaffected if the [Ca2+] is not reduced to fully relaxing levels but to slightly activating levels leading to a residual steady-state force of only about 10% of maximum force. We recently confirmed these findings also for cardiac myofibrils (R. Stehle, unpublished data). The detailed molecular mechanism of the dependence of relaxation kinetics on the final force remains unclear. However, we presume that the observed decrease in kREL by the mutation does not directly reflect a slower switch-off of the thin filament (koff), which rate-limits the force decay, since this should even more sensitively affect the rate constant of the initial phase (kLIN) which was not the case. Instead we suggest that the reduction of kREL relates somehow to the effect of the mutation to increase the steady-state force at low [Ca2+] as indicated by the increased force–SL relation. The strong decrease in kREL with increasing final force might indicate a load dependence of sarcomere dynamics as known, for example, for the shortening velocity, which varies most steeply with load at low levels. Regardless of the molecular mechanism for the mutant-induced decrease in kREL, this slow-down in mechanical relaxation of myofibrils is expected to directly affect the rate of the isovolumetric pressure decay in the heart and could therefore be one of the main determinants of the decreased value of tau () found in the working heart analysis of cTnIR146G transgenic mice (James et al. 2000). This effect on the overall duration of force decline is even more pronounced in hcTnIR145G-exchanged myofibrils, since they additionally exhibit a prolonged linear phase (tLIN), which contributes to the overall relaxation period. Clinically, the impaired relaxation abilities of the contractile apparatus could explain the diastolic dysfunction of the heart, as typical for patients suffering from hypertrophic cardiomyopathy (Kass et al. 2004).
Maximum Ca2+-induced force development (Fmax/CSA)
In myofibrils exchanged in vitro the maximum force development at pCa 4.5 (Fmax/CSA) was significantly reduced. Interestingly, no changes were observed for Fmax/CSA in myofibrils isolated from the transgenic mice. Previous studies have already described a reduction of maximum force development in cTnIR145G-exchanged skinned fibre preparations and a significant reduction of maximum ATPase activity after incorporation of cTnIR145G in reconstituted thin filaments (Elliott et al. 2000; Takahashi-Yanaga et al. 2001; Burton et al. 2002). This is in agreement with our own results, as impaired maximum ATPase activity could be the underlying cause of the decreased Fmax/CSA in hcTnIR145G-exchanged myofibrils described in the present study.
Surprisingly, despite the decrease in kACT no changes were observed for Fmax/CSA in myofibrils from the transgenic mice. According to the model of Brenner (1988), kACT = fapp + gapp and force is proportional to fapp/(fapp + gapp), where fapp and gapp are the crossbridge attachment and detachment rates, respectively. Hence, changes in kACT should relate to changes in force and vice versa. As kLIN is not affected by the mutation we assume that the crossbridge detachment rate gapp is not altered. The mutation therefore can be regarded as affecting the Ca2+-regulated crossbridge attachment rate fapp. However, because the relation of kACT versus relative force is very steep at high forces, at high activating [Ca2+] changes in the crossbridge attachment rate fapp are more sensitively detected by force development kinetics than by the force itself. This is the most likely reason why we do not find significant changes in Fmax/CSA between myofibrils from non-transgenic and transgenic mice. Future studies will have to show whether gene doses of the mutation can contribute to an effect of the mutation on Fmax/CSA in myofibrils from the transgenic animals compared with the biochemically exchanged myofibrils.
While kACT was significantly decreased in isolated cardiac myofibrils from the transgenic mice, James et al. (2000) reported an enhanced contractile function in working heart analysis, described by increased values of +dP/dt. We assume that the enhanced contractility observed on the organ level could at least in part be due to adaptational processes aiming to compensate the impaired contractility of the myofilaments.
In summary, to the best of our knowledge our work provides the first direct experimental evidence that FHC can impair kinetic properties of Ca2+-induced force activation and relaxation at the myofibrillar level. The present results lead to the conclusion that the cTnIR145G mutation primarily perturbs the interactions between cTnI–actin and cTnI–cTnC, thereby affecting crossbridge turnover kinetics, which could then underlie the impaired pressure dynamics found in the working heart of cTnIR146G transgenic animals. We therefore suggest that impaired myofibrillar relaxation could be a fundamental cause for FHC-induced diastolic dysfunction. As these changes were observed in a mouse line that exhibited no gross morphological pathology of the heart (James et al. 2000), our study also indicates that functional changes at the myofibrillar level may precede morphological changes. Whether the functional changes cause the hypertrophy and in particular whether they are relevant for the development of the disease in human patients remains to be seen. In addition we propose that the increased contractility detected in the working heart analysis of the transgenic animals may be due to an over-compensation of reduced myofibrillar contractility. More functional and clinical studies will be needed to further understand the physiological impacts of FHC-associated cTnI mutants and the regulatory processes finally leading to hypertrophy and heart failure.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Brenner
B (1988). Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers. Implications for regulation of muscle contraction. Proc Natl Acad Sci U S A
85, 3265–3269.
Brenner
B
&
Chalovich
JM (1999). Kinetics of thin filament activation probed by fluorescence of N-(2-(iodoacetosylethyl)-N-methyl) amino-7-nitrobenz-2-oxa-1,3-diazole-labeled troponin I incorporated into skinned fibers of rabbit psoas muscle: implications for regulation of muscle contraction. Biophys J
77, 2692–2708.
Brenner
B, Kraft
T, Yu
LC
&
Chalovich
JM (1999). Thin-filament activation probed by fluorescence of N-(2-(iodoacetosylethyl)-N-methyl) amino-7-nitrobenz-2-oxa-1,3-diazole-labeled troponin I incorporated into skinned fibers of rabbit psoas muscle. Biophys J
77, 2677–2691.
Burton D, Abdulrazzak H, Knott A, Elliott K, Redwood C, Watkins H et al. (2002). Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility. Biochem J 362, 443–451.[CrossRef][Medline]
Elliott
K, Watkins
H
&
Redwood
CS (2000). Altered regulator properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem
275, 22069–22074.
Evans
CC, Pena
JR, Phillips
RM, Muthuchamy
M, Wieczorek
DF, Solaro
RJ
et al. (2000). Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol
279, H2414–2423.
Fatkin
D
&
Graham
RM (2002). Molecular mechanisms of inherited cardiomyopathies. Physiol Rev
82, 945–980.
Gordon
AM, Homsher
E
&
Regnier
M (2000). Regulation of contraction in striated muscle. Physiol Rev
80, 853–924.
James
J, Zhang
Y, Osinska
H, Sanbe
A, Klevitsky
R, Hewett
TE
et al. (2000). Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res
87, 805–811.
Janssen
PM, Stull
LB
&
Marban
E (2002). Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat. Am J Physiol Heart Circ Physiol
282, H499–507.
Kass
DA, Bronzwaer
JGF
&
Paulus
WJ (2004). What mechanisms underlie diastolic dysfunction in heart failure?
Circ Res
94, 1533–1542.
Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M et al. (1997). Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 16, 379–382.[CrossRef][Medline]
Kohler
J, Chen
Y, Brenner
B, Gordon
AM, Kraft
T, Martyn
DA
et al. (2003). Familial hypertrophic cardiomyopathy mutations in troponin I (K183
, G203S, K206Q) enhance filament sliding. Physiol Genomics
14, 117–128.
Krenz
M, Sanbe
A, Bouyer-Dalloz
F, Gulick
J, Klevitsky
R, Hewett
TE
et al. (2003). Analysis of myosin heavy chain functionality in the heart. J Biol Chem
278, 17466–17474.
Kruger M, Pfitzer G & Stehle R (2003). Expression and purification of human cardiac troponin subunits and their functional incorporation into isolated cardiac mouse myofibrils. J Chromatogr B Anal Technol Biomed Life Sci 786, 287–296.[Medline]
Lang
R, Gomes
AV, Zhao
J, Housmans
PR, Miller
T
&
Potter
JD (2002). Functional analysis of a troponin I (R145G) mutation associated with familial hypertrophic cardiomyopathy. J Biol Chem
277, 11670–11678.
Li MX, Wang X, Lindhout DA, Buscemi N, Van Eyk JE & Sykes BD (2003). Phosphorylation and mutation of human cardiac troponin I deferentially destabilize the interaction of the functional regions of troponin I with troponin C. Biochemistry 42, 14460–14468.[CrossRef][Medline]
Marian AJ & Roberts R (1998). Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 9, 88–99.[Medline]
Martin
H, Bell
MG, Ellis-Davies
GC
&
Barsotti
RJ (2004). Activation kinetics of skinned cardiac muscle by laser photolysis of nitrophenyl-EGTA. Biophys J
86, 978–990.
Moss
RL, Razumova
M
&
Fitzsimons
DP (2004). Myosin crossbridge activation of cardiac thin filaments: implications for myocardial function in health and disease. Circ Res
94, 1290–1300.
Neagoe
C, Kulke
M, del Monte
F, Gwathmey
JK, de Tombe
P, Hajjar
RJ
et al. (2002). Titin isoform switch in ischemic human heart disease. Circulation
106, 1333–1341.
Ng
WA, Grupp
IL, Subramaniam
A
&
Robbins
J (1991). Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart. Circ Res
68, 1742–1750.
Palmer
S
&
Kentish
JC (1998). Roles of Ca2+ and crossbridge kinetics in determining the maximum rates of Ca2+ activation and relaxation in rat and guinea pig skinned trabeculae. Circ Res
83, 179–186.
Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR, Fananapazir L & Warshaw DM (2000). R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil 21, 609–620.[CrossRef][Medline]
Poggesi C, Tesi C & Stehle R (2005). Sarcomeric determinants of striated muscle relaxation kinetics. Pflugers Arch (in press).
Potter JD (1982). Preparation of troponin and its subunits. Meth Enzymol 85, 241–263.[Medline]
Seidman JG & Seidman C (2001). The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104, 557–567.[CrossRef][Medline]
Solaro
RJ
&
Rarick
HM (1998). Troponin and tropomyosin – proteins that switch on and tune in the activity of cardiac myofilaments. Circ Res
83, 471–480.
Stehle
R, Kruger
M
&
Pfitzer
G (2002a). Force kinetics and individual sarcomere dynamics in cardiac myofibrils after rapid Ca2+changes. Biophys J
83, 2152–2161.
Stehle R, Kruger M, Scherer P, Brixius K, Schwinger RH & Pfitzer G (2002b). Isometric force kinetics upon rapid activation and relaxation of mouse, guinea pig and human heart muscle studied on the subcellular myofibrillar level. Basic Res Cardiol 97, I127–135.[Medline]
Takahashi-Yanaga F, Morimoto S & Ohtsuki I (2001). Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 33, 2095–2107.[CrossRef][Medline]
Tesi
C, Piroddi
N, Colomo
F
&
Poggesi
C (2002). Relaxation kinetics following sudden Ca2+ reduction in single myofibrils from skeletal muscle. Biophys J
83, 2142–2151.
Tripet B, Van Eyk JE & Hodges RS (1997). Mapping of a second actin-tropomyosin and a second troponin C binding site within the C terminus of troponin I, and their importance in the Ca2+-dependent regulation of muscle contraction. J Mol Biol 271, 728–750.[CrossRef][Medline]
Van Eyk JE, Strauss JD, Hodges RS & Ruegg JC (1993). A synthetic peptide mimics troponin I function in the calcium-dependent regulation of muscle contraction. FEBS Lett 323, 223–228.[CrossRef][Medline]
Westfall
MV, Borton
AR, Albayya
FP
&
Metzger
JM (2002). Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants. Circ Res
91, 525–531.
Zhao
L, Naber
N
&
Cooke
R (1995). Muscle cross-bridges bound to actin are disordered in the presence of 2,3-butanedione monoxime. Biophys J
68, 1980–1990.
|
Acknowledgements |
|---|
This article has been cited by other articles:
|
|
 |
|
  M. P. Sumandea, V. O. Rybin, A. C. Hinken, C. Wang, T. Kobayashi, E. Harleton, G. Sievert, C. W. Balke, S. J. Feinmark, R. J. Solaro, et al. Tyrosine Phosphorylation Modifies Protein Kinase C {delta}-dependent Phosphorylation of Cardiac Troponin I J. Biol. Chem., August 15, 2008; 283(33): 22680 - 22689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wen, J. R. Pinto, A. V. Gomes, Y. Xu, Y. Wang, Y. Wang, J. D. Potter, and W. G. L. Kerrick Functional Consequences of the Human Cardiac Troponin I Hypertrophic Cardiomyopathy Mutation R145G in Transgenic Mice J. Biol. Chem., July 18, 2008; 283(29): 20484 - 20494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ochala, M. Li, M. Ohlsson, A. Oldfors, and L. Larsson Defective regulation of contractile function in muscle fibres carrying an E41K {beta}-tropomyosin mutation J. Physiol., June 15, 2008; 586(12): 2993 - 3004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsoutsman, M. Kelly, D. C.H. Ng, J.-E. Tan, E. Tu, L. Lam, M. A. Bogoyevitch, C. E. Seidman, J.G. Seidman, and C. Semsarian Severe Heart Failure and Early Mortality in a Double-Mutation Mouse Model of Familial Hypertrophic Cardiomyopathy Circulation, April 8, 2008; 117(14): 1820 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Davis and S. B. Tikunova Ca2+ exchange with troponin C and cardiac muscle dynamics Cardiovasc Res, March 1, 2008; 77(4): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Iorga, N. Blaudeck, J. Solzin, A. Neulen, I. Stehle, A. J. L. Davila, G. Pfitzer, and R. Stehle Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils Cardiovasc Res, March 1, 2008; 77(4): 676 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Davis, H. Wen, T. Edwards, and J. M. Metzger Thin Filament Disinhibition by Restrictive Cardiomyopathy Mutant R193H Troponin I Induces Ca2+-Independent Mechanical Tone and Acute Myocyte Remodeling Circ. Res., May 25, 2007; 100(10): 1494 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Moreno-Gonzalez, T. E. Gillis, A. J. Rivera, P. B. Chase, D. A. Martyn, and M. Regnier Thin-filament regulation of force redevelopment kinetics in rabbit skeletal muscle fibres J. Physiol., March 1, 2007; 579(2): 313 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stehle, B. Iorga, and G. Pfitzer Calcium regulat |
) 
